scRNA-seq, WES, and bulk RNA-seq on longitudinal samples from 7 Lymphoma patients treated with CD20xCD3 bispecific antibodies
We performed scRNA-seq on 15 fresh lymph node core biopsies from 7 Lymphoma patients treated with CD20xCD3 bispecific antibodies. We also performed whole-exome sequencing (WES) and bulk RNA-seq on formalin-fixed paraffin embedded (FFPE) tumor samples from these patients. WES was additionally performed on matched germline samples (blood) for each patient.
- 29 samples
- DAC: EGAC00001003426
- Technology: Illumina NovaSeq 6000
Data access policy for scRNA-seq, whole-exome sequencing (WES), and bulk RNA-seq data generated in the study of resistance mechanisms of Lymphoam to CD20xCD3 bispecific antibody products.
Access to generated data is made available by completing the data access agreement for review by the data access committee and will be granted exclusively to qualified investigators for appropriate use.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |